Therefore, as HO‐3867 is reported to target p53,34 STAT3,29 JNK1/2 and IAPs, HO‐3867 would be a potential therapeutic approach for treatment of OSCC or other types of cancers that may have dysregulation of p53, STAT3, JNK1/2 and IAPs. This evidence concerns the gene TP53 and cancer.